PeerView Gastroenterology CME/CNE/CPE Audio Podcast PeerView

Go online to PeerView.com/BJF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease that is triggered by food and/or environmental allergens. It is characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. EoE affects about 1 in 2,000 people in the United States, and its prevalence is increasing. Until recently, there were no FDA-approved therapies, and management was limited to dietary approaches, drugs such as proton pump inhibitors and topical corticosteroids, and esophageal dilation. Targeted biologic therapies, some of which are already approved for other type 2 inflammatory disorders, are now available or are in development for the treatment of EoE. A recent PeerView live event helped to prepare clinicians to appropriately use these agents and offered a patient perspective on disease burden, the disconnect between symptoms and disease activity, and the need for continuous monitoring and maintenance treatment. The expert faculty offered recommendations for pediatric patient populations and told the “Story Behind the Science,” adding meaning to the data. If you couldn’t attend the live event, check out this on-demand version now! Upon completion of this activity, participants should be better able to: Discuss the burden of eosinophilic esophagitis (EoE) on patient/caregiver quality of life, the progressive nature of the disease, and the need for continuous monitoring and treatment, thereby improving the standard of care; Recognize the role of underlying type 2 inflammation in the development and progression of EoE and describe the rationale for targeted treatment, particularly when type 2 comorbidities are present; and Employ the latest expert recommendations and clinical evidence to treat patients with EoE, including pediatric populations, using a shared decision-making approach.

Go online to PeerView.com/RVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses NAFLD and NASH as metabolic diseases and potential therapeutic targets for patients with the conditions. Upon completion of this activity, participants should be better able to: Describe the disease pathways and mechanisms that define NAFLD/NASH as metabolic diseases; Discuss the pathophysiology and role of GLP-1 as a therapeutic target in NAFLD/NASH and other metabolic conditions; Use noninvasive tests and biomarkers to monitor NAFLD/NASH disease progression; and Initiate early guideline-driven and pathway-driven management with available and emerging pharmacotherapies to delay NAFLD/NASH progression and improve outcomes for patients

Go online to PeerView.com/NXP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Emerging evidence supporting modern targeted strategies for the management of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has led to the development of several agents to personalize therapy based on molecular findings. In this activity, our expert faculty will provide updates on evolving evidence-based practice standards and discuss how to effectively integrate the latest treatment advances into practice. You will learn to identify appropriate baseline diagnostic testing to inform the selection of targeted therapy for your patients with gastrointestinal cancers. Our experts will also introduce the latest evidence supporting relevant, novel strategies and explain when to initiate these agents in comparison with conventional treatment. Upon completion of this activity, participants should be better able to: Recognize current evidence supporting molecular testing, including HER2 expression, and its role in treatment selection for patients with HER2-positive GI cancers; Implement personalized treatment strategies based on molecular findings, current evidence and recommendations, and patient-specific factors when managing HER2-expressing GI cancers; and Apply practical strategies to manage and mitigate treatment-related AEs associated with HER2-targeting agents when managing BTC and GEA.

Go online to PeerView.com/RZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with irritable bowel syndrome with constipation (IBS-C) are often more comfortable discussing their concerns with the nurses on their healthcare team, which demonstrates the need for team-based care in order to maximize management, enhance outcomes, and improve quality of life. This activity features an expert overview of the pathophysiology of IBS-C and targets for therapy, including novel NHE3 inhibitors, as well as evidence-based treatment approaches with a focus on identifying and overcoming barriers to guideline-based care. Hear about recent advances in the diagnosis and treatment of IBS-C, specifically the mechanisms of the condition, current and emerging therapies, and coordinated approaches for overcoming barriers to care. Upon completion of this activity, participants should be better able to: Describe the pathophysiology and potential therapeutic targets for IBS-C; Use patient-centered tactics and tools to overcome barriers to guideline-directed IBS-C management; and Create team-based approaches to IBS-C management in accordance with current evidence and guidelines, recognizing the appropriate use of current and emerging therapeutic agents

Go online to PeerView.com/TGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. Diagnosis of EoE is frequently missed or delayed, which can lead to such complications as esophageal stricture and reduced patient quality of life. Fortunately, targeted biologic therapies already approved for other type 2 inflammatory disorders are approved, or are in development, for the treatment of EoE and appear promising. This case-based activity will offer expert insights for recognizing and diagnosing EoE, monitoring and managing EoE, and integrating targeted therapies into practice. Upon completion of this activity, participants should be better able to: Diagnose eosinophilic esophagitis (EoE) promptly according to the latest guidelines and criteria to decrease the risk of complications precipitated by uncontrolled disease; Apply the latest clinical research developments and updates in treatment guidelines to the management of EoE in collaboration with the healthcare team; and Select treatment, including novel targeted biologic therapies, for patients with EoE based on the latest clinical evidence

Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies and the importance of integrating systemic therapy into earlier stages of disease. Upon completion of this activity, participants should be better able to: Summarize clinical evidence on approved and emerging immunotherapy, targeted, antiangiogenic, and combination-based platforms across HCC settings and patient populations; Recommend individualized, evidence-based approaches to treatment selection and sequencing for patients with advanced HCC over multiple lines of therapy; and Develop strategies to improve treatment delivery, tolerability, and safety management for patients with HCC receiving modern therapies